{"id":34944,"date":"2024-02-06T17:15:20","date_gmt":"2024-02-06T15:15:20","guid":{"rendered":"https:\/\/irb.usi.ch\/?p=34944"},"modified":"2024-02-06T17:15:20","modified_gmt":"2024-02-06T15:15:20","slug":"targeting-licensed-immune-cells-in-cancer-therapy-a-new-frontier-for-the-future","status":"publish","type":"post","link":"https:\/\/irb.usi.ch\/it\/events\/targeting-licensed-immune-cells-in-cancer-therapy-a-new-frontier-for-the-future\/","title":{"rendered":"Targeting licensed immune cells in cancer therapy: a new frontier for the future"},"content":{"rendered":"<p><strong>IRB Special Seminar<\/strong><\/p>\n<p><strong>Prof. Domenico Mavilio<br \/>\n<\/strong>Principal Investigator, Head, Unit of Clinical and Experimental Immunology, Department of Medical Biotechnologies and Translational Medicine, Medical School of Milan University, Humanitas Research Hospital, Rozzano, Milan (IT)<\/p>\n<p>Thursday, February 29, 2024<br \/>\nat 12:00 pm<br \/>\nBios+ Seminar Room<\/p>\n<p>Contact: Prof. Greta Guarda<\/p>\n","protected":false},"excerpt":{"rendered":"<p>IRB Special Seminar Prof. Domenico Mavilio Principal Investigator, Head, Unit of Clinical and Experimental Immunology, Department of Medical Biotechnologies and Translational Medicine, Medical School of Milan University, Humanitas Research Hospital, Rozzano, Milan (IT) Thursday, February 29, 2024 at 12:00 pm Bios+ Seminar Room Contact: Prof. Greta Guarda<\/p>\n","protected":false},"author":136,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[12],"tags":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v15.7 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Targeting licensed immune cells in cancer therapy: a new frontier for the future - IRB USI<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/irb.usi.ch\/it\/events\/targeting-licensed-immune-cells-in-cancer-therapy-a-new-frontier-for-the-future\/\" \/>\n<meta property=\"og:locale\" content=\"it_IT\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Targeting licensed immune cells in cancer therapy: a new frontier for the future - IRB USI\" \/>\n<meta property=\"og:description\" content=\"IRB Special Seminar Prof. Domenico Mavilio Principal Investigator, Head, Unit of Clinical and Experimental Immunology, Department of Medical Biotechnologies and Translational Medicine, Medical School of Milan University, Humanitas Research Hospital, Rozzano, Milan (IT) Thursday, February 29, 2024 at 12:00 pm Bios+ Seminar Room Contact: Prof. Greta Guarda\" \/>\n<meta property=\"og:url\" content=\"https:\/\/irb.usi.ch\/it\/events\/targeting-licensed-immune-cells-in-cancer-therapy-a-new-frontier-for-the-future\/\" \/>\n<meta property=\"og:site_name\" content=\"IRB USI\" \/>\n<meta property=\"article:published_time\" content=\"2024-02-06T15:15:20+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Tempo di lettura stimato\">\n\t<meta name=\"twitter:data1\" content=\"1 minuto\">\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebSite\",\"@id\":\"https:\/\/irb.usi.ch\/it\/#website\",\"url\":\"https:\/\/irb.usi.ch\/it\/\",\"name\":\"IRB USI\",\"description\":\"Institute for Research in Biomedicine\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":\"https:\/\/irb.usi.ch\/it\/?s={search_term_string}\",\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"it-IT\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/irb.usi.ch\/it\/events\/targeting-licensed-immune-cells-in-cancer-therapy-a-new-frontier-for-the-future\/#webpage\",\"url\":\"https:\/\/irb.usi.ch\/it\/events\/targeting-licensed-immune-cells-in-cancer-therapy-a-new-frontier-for-the-future\/\",\"name\":\"Targeting licensed immune cells in cancer therapy: a new frontier for the future - IRB USI\",\"isPartOf\":{\"@id\":\"https:\/\/irb.usi.ch\/it\/#website\"},\"datePublished\":\"2024-02-06T15:15:20+00:00\",\"dateModified\":\"2024-02-06T15:15:20+00:00\",\"author\":{\"@id\":\"https:\/\/irb.usi.ch\/it\/#\/schema\/person\/01bacbaaa75ea23cfc275a8fb0e0ab94\"},\"breadcrumb\":{\"@id\":\"https:\/\/irb.usi.ch\/it\/events\/targeting-licensed-immune-cells-in-cancer-therapy-a-new-frontier-for-the-future\/#breadcrumb\"},\"inLanguage\":\"it-IT\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/irb.usi.ch\/it\/events\/targeting-licensed-immune-cells-in-cancer-therapy-a-new-frontier-for-the-future\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/irb.usi.ch\/it\/events\/targeting-licensed-immune-cells-in-cancer-therapy-a-new-frontier-for-the-future\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"item\":{\"@type\":\"WebPage\",\"@id\":\"https:\/\/irb.usi.ch\/it\/\",\"url\":\"https:\/\/irb.usi.ch\/it\/\",\"name\":\"Home\"}},{\"@type\":\"ListItem\",\"position\":2,\"item\":{\"@type\":\"WebPage\",\"@id\":\"https:\/\/irb.usi.ch\/.\/events\/\",\"url\":\"https:\/\/irb.usi.ch\/.\/events\/\",\"name\":\"Events\"}},{\"@type\":\"ListItem\",\"position\":3,\"item\":{\"@type\":\"WebPage\",\"@id\":\"https:\/\/irb.usi.ch\/it\/events\/targeting-licensed-immune-cells-in-cancer-therapy-a-new-frontier-for-the-future\/\",\"url\":\"https:\/\/irb.usi.ch\/it\/events\/targeting-licensed-immune-cells-in-cancer-therapy-a-new-frontier-for-the-future\/\",\"name\":\"Targeting licensed immune cells in cancer therapy: a new frontier for the future\"}}]},{\"@type\":\"Person\",\"@id\":\"https:\/\/irb.usi.ch\/it\/#\/schema\/person\/01bacbaaa75ea23cfc275a8fb0e0ab94\",\"name\":\"Andrea Nava\",\"sameAs\":[\"https:\/\/irb.usi.ch\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","_links":{"self":[{"href":"https:\/\/irb.usi.ch\/it\/wp-json\/wp\/v2\/posts\/34944"}],"collection":[{"href":"https:\/\/irb.usi.ch\/it\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/irb.usi.ch\/it\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/irb.usi.ch\/it\/wp-json\/wp\/v2\/users\/136"}],"replies":[{"embeddable":true,"href":"https:\/\/irb.usi.ch\/it\/wp-json\/wp\/v2\/comments?post=34944"}],"version-history":[{"count":1,"href":"https:\/\/irb.usi.ch\/it\/wp-json\/wp\/v2\/posts\/34944\/revisions"}],"predecessor-version":[{"id":34945,"href":"https:\/\/irb.usi.ch\/it\/wp-json\/wp\/v2\/posts\/34944\/revisions\/34945"}],"wp:attachment":[{"href":"https:\/\/irb.usi.ch\/it\/wp-json\/wp\/v2\/media?parent=34944"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/irb.usi.ch\/it\/wp-json\/wp\/v2\/categories?post=34944"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/irb.usi.ch\/it\/wp-json\/wp\/v2\/tags?post=34944"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}